News
BDXB
48.16
0.00%
0.00
BD SAYS CEO PAY RATIO FOR 2024 WAS 396 TO 1
Reuters · 12/19/2024 15:42
BD SAYS CEO THOMAS POLEN'S 2024 TOTAL COMPENSATION WAS $17.3 MLN - SEC FILING
Reuters · 12/19/2024 15:42
BECTON DICKINSON AND CO - NOT UPDATING FISCAL 2025 GUIDANCE DUE TO SETTLEMENT
Reuters · 12/16/2024 21:32
BD RESOLVES PREVIOUSLY DISCLOSED SEC INVESTIGATION
Reuters · 12/16/2024 21:32
U.S. SEC SAYS BECTON DICKINSON TO PAY $175 MILLION FOR MISLEADING INVESTORS ABOUT ALARIS INFUSION PUMP
Reuters · 12/16/2024 21:28
BRIEF-Maravai Lifesciences Appoints R. Andrew Eckert As Chairman Of The Board Of Directors
Reuters · 12/05/2024 21:33
BECTON, DICKINSON AND COMPANY <BDX.N>: WELLS FARGO CUTS TARGET PRICE TO $275 FROM $280
Reuters · 11/08/2024 11:32
BUZZ-U.S. STOCKS ON THE MOVE-BorgWarner, Digital Realty, Take-Two
Reuters · 11/07/2024 19:04
BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, CoreCivic, WK Kellogg
Reuters · 11/07/2024 15:52
Becton Dickinson and Co reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07/2024 14:42
BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, AppLovin, Sarepta
Reuters · 11/07/2024 14:22
BUZZ-Becton Dickinson climbs after Q4 results beat
Reuters · 11/07/2024 13:18
BD SHARES UP 2.5% PREMARKET AFTER Q4 RESULTS BEAT
Reuters · 11/07/2024 13:09
Becton Dickinson beats quarterly estimates on strength in drug-delivery devices
Reuters · 11/07/2024 12:40
BRIEF-Becton Dickinson Q4 Adjusted EPS USD 3.81 Vs. IBES Estimate USD 3.77
Reuters · 11/07/2024 11:30
BD REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2024 FINANCIAL RESULTS
Reuters · 11/07/2024 11:30
BD - ISSUES FY25 REVENUE GUIDANCE INCLUDING GAAP GROWTH OF 8.9% TO 9.4%, ADJUSTED CURRENCY-NEUTRAL GROWTH OF 8.8% TO 9.3%
Reuters · 11/07/2024 11:30
BD OUTLOOK FY 2025 GAAP REV $21.9 TO $22.1 BLN
Reuters · 11/07/2024 11:30
More
Webull provides a variety of real-time BDXB stock news. You can receive the latest news about Becton Dickinson And Co through multiple platforms. This information may help you make smarter investment decisions.
About BDXB
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.